Dyne Therapeutics Inc.
- Address
- 1560 Trapelo Road
Sponsor Overview
Specializations
Duchenne muscular dystrophy
Clinical research in Duchenne muscular dystrophy focuses on muscle disease affecting strength and mobility, with attention to restoring dystrophin expression in skeletal muscle tissue.
- Muscle function
- Dystrophin protein
- Skeletal muscle involvement
These studies examine therapeutic interest in progressive neuromuscular impairment and the biological markers linked to muscle integrity.
Myotonic dystrophy type 1
Research in myotonic dystrophy type 1 centers on inherited neuromuscular disorder symptoms, including hand myotonia and broader functional limitations.
- Hand myotonia
- Muscle function
- Neuromuscular symptoms
The therapeutic focus includes assessment of changes in muscle performance and disease-related motor impairment.
Neuromuscular therapeutics
The sponsor’s portfolio reflects a concentrated interest in neuromuscular therapeutics, with programs directed toward inherited muscle disorders and their functional consequences.
- Inherited muscle disease
- Motor function
- Muscle pathology
Research activity includes evaluation of clinically relevant outcomes tied to muscle performance and disease burden.
Muscle tissue biomarkers
Investigations also emphasize muscle tissue biomarkers used to track biological response in neuromuscular disease, including measures associated with protein expression and tissue-level change.
- Protein expression
- Tissue-level response
- Biological markers
This area aligns with research into measurable indicators of treatment effect in chronic muscle disorders.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of DYNE-101 in Participants with Myotonic Dystrophy Type 1: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study |  Belgium Denmark France Germany Italy Spain The Netherlands | Recruiting |
| Evaluation of Safety, Tolerability, and Efficacy of DYNE-251 in Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping | Belgium Ireland Italy Spain | Not Recruiting |
| Evaluation of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DYNE-101 in Myotonic Dystrophy Type 1 Patients | France Germany Italy The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 4 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 29 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases3 trials238 other sponsors
- 2.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
29 centres- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Via Di Grottarossa 1035-1039, 00189 Rome
- Address
- Boulevard Du Douzieme De Ligne 1, 4000 Liège
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Dyne Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.